Scientific Advisory Board 
Jonathan Schneck, M.D., Ph.D.
Chairman of the Scientific and Clinical Advisory Board
Professor of Pathology and Oncology at Johns Hopkins School of Medicine
For several years, Dr. Schneck’s laboratory has studied the modulation of T cell function in healthy and disease states. He is well known for several key scientific contributions including extensive work in the artificial manipulation of immune system components in order to maximize T cell response. To facilitate the study of immune function he and his laboratory have developed a variety of innovative nano-molecular tools including the Synthetic Antigen Presenting Cell (aAPC) technology that is foundation for AIMTM technology. These tools allow his laboratory to focus on multi-scale and multidimensional analysis of the T cell responses enhancing insights into both the basic biology of T cells responses and ultimately mechanisms for the development of novel therapeutics. The power and potential of Dr. Schneck’s work has been recognized with excellent support by NIH; Dr. Schneck is leading a team of investigators that were awarded a $10 Million grant in 2009, the largest immunology grant in the history of Johns Hopkins University. Dr. Schneck has more than 200 scientific publications and is an inventor on several dozen submitted and granted patents.

Mathias Oelke, Ph.D.
Assistant Professor in the Pathology and Oncology Departments at The Johns Hopkins University School of Medicine

Dr. Oelke’s research focuses on new tools for antigen-specific T cell detection and modulation. He is a co-inventor and a key contributor to the development of the AIM technology. His work in this area has been recognized in both scientific and lay press including Trends in Biotechnology and BioWorld, and NPR. Dr. Oelke is a respected investigator in the field of human T cell immunology and cancer immunotherapy with an international network of collaborations. He is currently conducting research on T cell immunomodulation to develop new approaches for active and adoptive immunotherapy for the treatment of cancer and T cell mediated autoimmune diseases such as diabetes, autoimmune hepatitis and transplant protection. He has more than 25 scientific publications and is an inventor on more than 10 submitted and granted patents.

NexImmune is finalizing agreements with several clinical and scientific advisers.